Data / Drug companies / Pitavastatin calcium
Pitavastatin calcium: 10 companies and 29 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Pitavastatin calcium is listed in the FDA National Drug Code Directory by 10 companies, with 29 products in commercial distribution. 26 of the products (89.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, and the newest product started marketing on September 18, 2025.
The request: Get every company that lists pitavastatin calcium in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 29
- Generic (ANDA) products
- 26 (89.7%)
- Application numbers
- 5
- Routes
- Oral
- Brand names
- Pitavastatin, Livalo
- openFDA record search
- api.fda.gov
Companies that list pitavastatin calcium
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| AvKARE | 3 | tablet, film coated | Generic drugs (ANDA) | January 16, 2024 |
| Camber Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | April 30, 2024 |
| Golden State Medical Supply, Inc. | 3 | tablet | Generic drugs (ANDA) | February 3, 2017 |
| Kowa Pharmaceuticals America, Inc. | 3 | tablet, film coated | New drug applications (NDA) | May 16, 2019 |
| Teva Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | November 2, 2023 |
| Upsher-Smith Laboratories, LLC | 3 | tablet | Generic drugs (ANDA) | November 2, 2023 |
| XLCare Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | September 18, 2025 |
| Zydus Lifesciences Limited | 3 | tablet | Generic drugs (ANDA) | November 2, 2023 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet | Generic drugs (ANDA) | November 2, 2023 |
| NorthStar RxLLC | 2 | tablet, film coated | Generic drugs (ANDA) | December 1, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 17 | 58.6% |
| Tablet | 12 | 41.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 89.7% |
| New drug applications (NDA) | 3 | 10.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| HMG-CoA Reductase Inhibitor | 29 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.